Protective role of IL-2 during activation of T cells with bryostatin 1

International Journal of Immunopharmacology

Volumn 22, Issue 8, 2000, Pages 645-652

  Kos, Ferdynand J ^a,c   Cornell, David L ^b   Lipke, Anne B ^b   Graham, Laura J ^b   Bear, Harry D ^b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bryostatin; CD25; IL 2; T cell activation; Tumor immunotherapy

Indexed keywords

BRYOSTATIN 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IN VITRO STUDY; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; INTERLEUKIN-2; LACTONES; LYMPHOCYTE ACTIVATION; MACROLIDES; MICE; MICE, INBRED BALB C; PROTEIN KINASE C; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0034257226     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00027-8     Document Type: Article

References (38)

1. Pettit G.R. The bryostatins. Herz W., Kirby G.W., Steglich W., Tamm C. Progress in the chemistry of organic natural products. 1991;153-195 Springer-Verlag, Vienna, New York.
2. Hornung R.L., Pearson J.W., Beckwith M., Longo D.L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 52:1992;101-107.
3. Kraft A.S., Woodley S., Pettit G.R., Gao F., Coll J.C., Wagner F. Comparison of the antitumor activity of bryostatins 1, 5, and 8. Cancer Chemother Pharmacol. 37:1996;271-278.
4. Trenn G., Pettit G.R., Takayama H., Hu-Li J., Sitkovsky M.V. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J. Immunol. 140:1988;433-439.
5. Hess A.D., Silanskis M.K., Esa A.H., Pettit G.R., May W.S. Activation of human T lymphocytes by bryostatin. J. Immunol. 141:1988;3263-3269.
6. Tuttle T.M., Inge T.H., Bethke K.P., McCrady C.W., Pettit G.R., Bear H.D. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res. 52:1992;548-553.
7. Thoburn C.J., Hess A.D. Bryostatin can induce antigen-specific nonresponsiveness in human peripheral blood T cells. Transpl. Proc. 27:1995;443-444.
8. Fleming M.D., Bear H.D., Lipshy K., Kostuchenko P.J., Portocarero D., et al. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. J. Immunother. 18:1995;147-155.
9. + T lymphocyte effector responses. J. Immunol. 159:1997;582-590.
10. Isakov N., Galron D., Mustelin T., Pettit G.R., Altman A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J. Immunol. 150:1993;1195-1204.
11. Szallasi Z., Denning M.F., Smith C.B., Dlugosz A.A., Yuspa S.H., et al. Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol. Pharmacol. 46:1994;840-850.
12. 2+ signals restore mitogenic activity without abrogating enhanced cPKC degradation. Cell Immunol. 158:1994;195-207.
13. Lee H.W., Smith L., Pettit G.R., Bingham Smith. J. Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin. Am. J. Physiol. 271:1996;C304-C311.
14. Bear H.D., McFadden A.W., Kostuchenko P.J., Lipshy K.A., Hamad G.G., et al. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration. Anti-Cancer Drugs. 7:1996;299-306.
15. Kos F.J., Bear H.D. Involvement of protein kinase C-δ in CD28-triggered cytotoxicity mediated by a human leukaemic cell line YT. Immunology. 94:1998;575-579.
16. Wang H., Mohammad R.M., Werdell J., Shekhar P.V.M. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: in vitro versus in vivo activity. Int. J. Mol. Med. 1:1998;915-923.
17. Scheid C., Prendiville J., Jayson G., Crowther D., Fox B., et al. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase I clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol. Immunother. 39:1994;223-230.
18. 31P magnetic resonance spectroscopic study. Br. J. Cancer. 72:1995;998-1003.
19. Jayson G.C., Crowther D., Prendiville J., McGown A.T., Scheid C., et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer. 72:1995;461-468.
20. Grant S., Roberts J., Poplin E., Tombes M.B., Kyle B., et al. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin. Cancer Res. 4:1998;611-618.
21. Propper D.J., Macaulay V., O'Byrne K.J., Braybrooke J.P., Wilner S.M., et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br. J. Cancer. 78:1998;1337-1341.
22. Tuttle T.M., Inge T.H., Wirt C.P., Frank J.L., McCrady C.M., Bear H.D. Bryostatin 1 activates T cells that have antitumor activity. J. Immunother. 12:1992;75-81.
23. Tsai S.-C.J., Gansbacher B., Tait L., Miller F.R., Heppner G.H. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl. Cancer Inst. 85:1993;546-553.
24. Hathcock K.S. T cell enrichement by nonadherence to nylon. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. Current protocols in immunology. 1996;3.2.1-3.2.4 John Wiley & Sons, New York.
25. Miller B.E., Miller F.R., Wilburn D., Heppner G.H. Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res. 48:1988;5747-5753.
26. Esa A.H., Boto W.O., Adler W.H., May W.S., Hess A.D. Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors. Int. J. Immunopharmacol. 12:1990;481-490.
27. Szamel M., Appel A., Schwinzer R., Resch K. Different protein kinase C isoenzymes regulate IL-2 receptor expression or IL-2 synthesis in human lymphocytes stimulated via the TCR. J. Immunol. 160:1998;2207-2214.
28. Kos F.J., Müllbacher A. IL-2-independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro. J. Immunol. 150:1993;387-393.
29. + memory cytotoxic T cells. Can. J. Microbiol. 39:1993;141-157.
30. Razvi E.S., Welsh R.M., McFarland H.I. In vivo state of antiviral CTL precursors. Characterization of a cycling cell population containing CTL precursors in immune mice. J. Immunol. 154:1995;620-632.
31. Kos F.J., Müllbacher A. Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7. Eur. J. Immunol. 22:1992;3183-3185.
32. Weiss A., Littman D.R. Signal transduction by lymphocyte antigen receptors. Cell. 76:1994;263-274.
33. Szamel M., Resch K. T-cell antigen receptor-induced signal-transduction pathways. Activation and function of protein kinase C in T lymphocytes. Eur. J. Biochem. 228:1995;1-15.
34. Monks C.R., Kupfer H., Tamir I., Barlow A., Kupfer A. Selective modulation of protein kinase C-θ during T-cell activation. Nature. 385:1997;83-86.
35. + human T lymphocyte subsets. Eur. J. Immunol. 23:1993;61-68.
36. Höllsberg P., Melinek J., Benjamin D., Hafler D.A. Increased protein kinase C activity in human memory T cells. Cell Immunol. 149:1993;170-179.
37. + T lymphocytes. Immunology. 85:1995;299-303.
38. + and can be selectively activated with phorbol ester and calcium ionophore. Cell Immunol. 113:1988;268-277.